Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer

The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.